Analyst Gena Wang of Jefferies commented on bluebird bio Inc (NASDAQ:BLUE) following management meetings on programs for pipeline gene therapies LentiGlobin, Lenti-D, and …
Analysts weighed in how the FDA clinical hold Juno Therapeutics Inc (NASDAQ:JUNO) received affects its business as well as companies with similar drugs …
A meeting with bluebird bio Inc’s (NASDAQ:BLUE) leadership last week validified Dane Leone’s, an analyst at BTIG, confidence in the company. The meeting …
bluebird bio Inc (NASDAQ:BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and rare diseases and T cell-based immunotherapies …
bluebird bio Inc (NASDAQ:BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, …
bluebird bio Inc (NASDAQ:BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for …
Leerink and Wedbush analysts highlight potential catalysts for Intercept Pharmaceuticals Inc (NASDAQ:ICPT) and bluebird bio Inc (NASDAQ:BLUE). One analyst believes that better than expected briefing …
In a research report released Friday, Piper Jaffray analyst Joshua Schimmer reiterated an Overweight rating on shares of bluebird bio Inc (NASDAQ:BLUE) with a …
Biotech analysts weighed in on specialty drug maker Valeant Pharmaceuticals Intl Inc (NYSE:VRX) and biotechnology firm bluebird bio Inc (NASDAQ:BLUE). The analysts are cautious on …
While the biotech tape remains a challenging one, Maxim analysts remain positive on drug maker Keryx Biopharmaceuticals (NASDAQ:KERX) and gene-therapy-product maker bluebird bio Inc (NASDAQ:BLUE). Below …
